The presumed low risk substances should be prioritised in accordance with Implementing Decision C(2016) 6104. The approval of those substances should therefore be extended by a period as short as possible. Taking into account the distribution of responsibilities and work among the Member States acting as rapporteurs and co-rapporteursand the available resources necessary for assessment and decision-making, that period should be of one year for the active substance prohexadione.
Recital 5, Regulation (EU) 2019/291
In forcesince 19 Feb 2019